Quest Diagnostics 株価情報 (NYSE: DGX)

Quest Diagnostics (NYSE:DGX) 株価情報

Quest Diagnostics

Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics Inc

Grail Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares are trading higher Wednesday after the company announced <a href="https://www.benzinga.com/insights/analyst-ratings/25/01/43401565/what-6-analyst-ratings-have-to-say-about-quest-diagnostics">a new collaboration with</a> Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>).
The partnership aims to improve provider access to its <a href="https://www.benzinga.com/pressreleases/25/01/n42964119/patient-reported-outcomes-for-grails-galleri-multi-cancer-early-detection-blood-test-published-in-">Galleri multi-cancer early detection test. </a>
What To Know: The move is expected to streamline test ordering and expand availability across Quest's nationwide network, but investor reaction suggests concerns about the immediate impact on GRAIL's business.
GRAIL and Quest Diagnostics revealed the initial phase of their partnership, which allows physicians to order the Galleri test directly through Quest's connectivity system. This integration will enable over 500,000 providers to seamlessly request the test, just as they do with other blood work, through Quest's Quanum laboratory portal and more than 900 electronic health record systems. Patients can also access the test at any of Quest's 7,400 locations without needing to bring a test kit to their blood draw appointment.
Grail president Josh Ofman emphasized the significance of this expansion, noting that early detection is critical for improving cancer outcomes. 
He pointed out that while there are established screenings for only five cancers, nearly 70% of cancer-related deaths come from those without recommended screening tests. By integrating the Galleri test into routine exams, GRAIL and Quest aim to address this gap and make early detection more accessible.
Quest Senior Vice President Mark Gardner highlighted that the collaboration builds on their ongoing efforts since 2021 to expand access to the test. He stated that the new ordering process should simplify adoption among healthcare providers, making it easier to incorporate Galleri into standard cancer screening protocols.
The Galleri test detects cancer signals in the bloodstream by identifying DNA fragments shed by tumors, offering a non-invasive way to screen for multiple types of cancer before symptoms appear. The test is prescription-only and recommended for adults at elevated cancer risk, such as those over 50.
Price Action: Grail shares were up 17.6% at $38.63 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-1024x523.png" alt="" class="wp-image-779657" style="width:478px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12154323/Screenshot-2025-02-12-at-15.42.59.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention">Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention</a></li>
</ul>
Image Via Shutterstock.

News

Movers

GRAL

Grail Shares Spiked Wednesday: What's Going On?

GRAIL's Galleri&nbsp;Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience&nbsp;
MENLO PARK, Calif. and SECAUCUS, N.J., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced the initial phase of a program to improve provider access to GRAIL's Galleri&#xAE; multi-cancer early detection (MCED) test. Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest's Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity system last year.

GRAIL And Quest Diagnostics Provide GRAIL's Galleri Multi-Cancer Early Detection Test Through The Quest Diagnostics Test Ordering System

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $173 to $180.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $180

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Outperform and raises the price target from $177 to $178.

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $178

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $166 to $170.

UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $170

Piper Sandler analyst David Westenberg reiterates Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $165 to $180.

Reiteration

Piper Sandler Reiterates Neutral on Quest Diagnostics, Raises Price Target to $180

Ratings for Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $178.33, a high estimate of $185.00, and a low estimate of $172.00. This current average has increased by 7.04% from the previous average price target of $166.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1738350021_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Quest Diagnostics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$182.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Quest Diagnostics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>All You Need to Know About Quest Diagnostics</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Key Indicators: Quest Diagnostics's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Quest Diagnostics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.41%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Quest Diagnostics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Quest Diagnostics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.5%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.02, Quest Diagnostics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 6 Analyst Ratings Have To Say About Quest Diagnostics

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Hold and raises the price target from $172 to $182.

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $182

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Equal-Weight and raises the price target from $168 to $175.

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $175

Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) shares are trading higher Thursday after the company reported better-than-expected financial results <a href="https://www.benzinga.com/pressreleases/25/01/n43331467/quest-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-guidance-fo">for the fourth quarter</a>.
What Happened: Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share. 
Total revenue was up 14.5% year-over-year, while earnings grew 14.7% year-over-year. 
Quest&#8217;s board authorized a 6.7% increase to the company&#8217;s quarterly dividend from 75 cents to 80 cents. The dividend will be payable on April 21 to shareholders of record as of April 7. 
&#8220;In the&nbsp;fourth quarter, we delivered impressive revenue growth of nearly&nbsp;15%, including approximately&nbsp;5%&nbsp;organic growth, while also improving our profitability,&#8221; said&nbsp;Jim Davis, chairman, president and CEO of Quest Diagnostics.
&#8220;For the full year, we drove revenue growth of close to&nbsp;7%, including approximately&nbsp;3%&nbsp;from organic growth. Our team completed eight acquisitions, including LifeLabs in&nbsp;Canada, expanded our advanced diagnostics portfolio, and extended our geographic and market reach with new clinical, consumer and health plan customers.&#8221;
See Also:<a href="https://www.benzinga.com/25/01/43342968/intel-q4-earnings-preview"> Intel Q4 Earnings Preview: CEO Search, PC Demand, Spinoffs On Watch</a>
Outlook: Quest Diagnostics expects full-year 2025 revenue to be in the range of $10.7 billion to $10.85 billion. The company expects earnings to be in the range of $8.34 to $8.59 per share, versus estimates of $8.82 per share. 
&#8220;Our&nbsp;guidance&nbsp;for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024,&#8221; Davis added.
DGX Price Action: <a href="http://benzinga.com/quote/dgx">Quest Diagnostics shares</a> were up 6.01% at $164.78 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Earnings

Quest Diagnostics Delivers Q4 Earnings Beat: The Details

Guidance

Earlier: Quest Diagnostics Sees FY25 Revenue $10.70B-$10.85B Vs $10.672B Est.

Reported Earlier, Quest Diagnostics Sees FY25 Adj. EPS $9.55-$9.80 Vs $9.75 Estimate

Dividends

Earlier: Quest Diagnostics Increased Its Quarterly Dividend From $0.75 To $0.80

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Thursday.
Shares of International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) gained 12.8% to $174.33 following the release of its fourth-quarter earnings, which surpassed analysts' expectations. The tech giant also unveiled its ambitious artificial intelligence strategy, further boosting <a href="https://www.benzinga.com/25/01/43321676/ibm-reports-q4">investor confidence</a>.
IBM reported earnings per share of $3.92, exceeding the anticipated $3.75. Revenue also edged past forecasts, reaching $17.55 billion compared to the projected $17.54 billion.
IBM shares climbed 13.7% to $259.86 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Tectonic Therapeutic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) shares jumped 97.5% to $50.80 after interim results showed TX45 achieved improvements in hemodynamics that met and exceeded prespecified objectives.</li>
<li>NetScout Systems, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCT#NASDAQ">NTCT</a>) gained 19.5% to $26.70 after the company reported better-than-expected quarterly financial results.</li>
<li>Flagstar Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) gained 16.6% to $11.19 after the company reported better-than-expected quarterly financial results.</li>
<li>Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) shares rose 15.4% to $110.40 after the company beat fourth-quarter EPS and revenue estimates, initiated FY25 EPS guidance above expectations and raised its quarterly dividend by 11%.</li>
<li>Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) gained 14% to $4.0000 after the company announced a $75.6 million public offering of class A common stock.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) rose 14% to $114.54 following better-than-expected fourth-quarter financial results and first-quarter guidance issued above estimates.</li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) shares gained 14% to $19.92 after Kerrisdale Capital announced a long position in the stock.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) rose 11.8% to $65.76.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) gained 10.5% to $40.76 after the company reported better-than-expected quarterly financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) rose 10.4% to $66.54.</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) gained 8.8% to $47.27 after the company reported better-than-expected quarterly revenue results.</li>
<li>Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) gained 8.5% to $221.22 following a fourth-quarter adjusted EPS and revenue beat..</li>
<li>Roper Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NYSE">ROP</a>) rose 7% to $579.97 after the company reported better-than-expected quarterly financial results.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) gained 7% to $4.75 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Domino&#8217;s Pizza, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) climbed 6.6% to $456.16.</li>
<li>Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) rose 5.5% to $164.07 following upbeat quarterly earnings.</li>
</ul>

Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

ACMR

BFLY

CALX

CHKP

CRDO

NTCT

SMTC

TECX

IBM Posts Upbeat Earnings, Joins Oshkosh, Las Vegas Sands, Nokia, Quest Diagnostics And Other Big Stocks Moving Higher On Thursday

WIIM

Quest Diagnostics shares are trading higher following better-than-expected Q4 earnings.

Quest Diagnostics Sees FY25 GAAP EPS $8.34-$8.59 Vs $8.82 Estimate

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported quarterly earnings of $2.23 per share which beat the analyst consensus estimate of $2.19 by 1.83 percent. This is a 3.72 percent increase over earnings of $2.15 per share from the same period last year. The company reported quarterly sales of $2.62 billion which beat the analyst consensus estimate of $2.58 billion by 1.65 percent. This is a 14.55 percent increase over sales of $2.29 billion the same period last year.

Earnings Beats

Quest Diagnostics Q4 2024 Adj EPS $2.23 Beats $2.19 Estimate, Sales $2.62B Beat $2.58B Estimate

AAPL

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

DECK

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

INTC

KLAC

KRNY

LPLA

MBLY

MBUU

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

SKYW

STBA

STEL

Earnings Scheduled For January 30, 2025

10 analysts have expressed a variety of opinions on Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $175.3, a high estimate of $185.00, and a low estimate of $165.00. This current average has increased by 9.26% from the previous average price target of $160.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200831_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Quest Diagnostics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$168.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Quest Diagnostics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Quest Diagnostics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Get to Know Quest Diagnostics Better</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Quest Diagnostics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Quest Diagnostics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.41%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.35%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Quest Diagnostics's Future

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $411 to $492. Keefe, Bruyette &amp; Woods analyst David Konrad maintained an Outperform rating. Tesla shares closed at $410.44 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners boosted Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) price target from $169 to $174. Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform. Quest Diagnostics shares closed at $151.92 on Friday. <a href="https://www.benzinga.com/quote/DGX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised the price target for FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) from $44 to $51. Citigroup analyst Atif Malik upgraded the stock from Neutral to Buy. FormFactor shares closed at $44.46 on Friday. <a href="https://www.benzinga.com/quote/FORM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased the price target for Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from $69 to $84. B of A Securities analyst Michael Cherny upgraded the stock from Underperform to Buy. Henry Schein shares closed at $69.09 on Friday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>Needham boosted Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) price target from $226 to $246. Needham analyst Tom Nikic maintained a Buy rating. Deckers Outdoor shares settled at $207.25 on Friday. <a href="https://www.benzinga.com/quote/DECK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) price target from $190 to $210. Barclays analyst David Strauss upgraded the stock from Equal-Weight to Overweight. Boeing shares closed at $169.90 on Friday. <a href="https://www.benzinga.com/quote/BA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) price target from $64 to $61. Jefferies analyst Lloyd Byrne maintained a Buy rating. SLB shares closed at $38.59 on Friday.  <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna raised the price target for C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from $115 to $130. Susquehanna analyst Bascome Majors upgraded the stock from Neutral to Positive. C.H. Robinson shares settled at $104.44 on Friday. <a href="https://www.benzinga.com/quote/CHRW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital cut 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) price target from $100 to $96. RBC Capital analyst Matthew Swanson maintained an Underperform rating. 3M shares closed at $129.87 on Friday. <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) price target from $677 to $639. Oppenheimer analyst Chris Kotowski maintained an Outperform rating. Goldman Sachs shares closed at $580.13 on Friday. <a href="https://www.benzinga.com/quote/GS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42816220/jim-cramer-likes-this-major-home-improvement-retailer-recommends-buying-it">Cramer: &#8216;At This Point,&#8217; SoundHound AI Rally &#8216;Is A Short Squeeze&#8217;</a></li>
</ul>

CHRW

FORM

HSIC

TSLA

Tesla To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Health Care

Press Releases

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025

Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer

Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals

Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share

Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year

GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

Quest Diagnostics to Host Investor Day on March 19, 2025

Small Cap

Opinion

Investors Eye Biotech Sector as Cancer Therapy Market Surges

MYNZ

ONCY

POAI

RENB

TSX:ONC

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Holdings

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

OPKO Health

Premier

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

JP Morgan

Mizuho

Piper Sandler

Truist Securities

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

General

Comments

Quest Diagnostics

ニュース

パートナーシップ

ベンジンガ・グローバル